BioXpress And Abzena Partner On Biosimilar Development

Alliance Will Aid Development And Manufacturing Of Biosimilars For Global Customers

BioXpress Therapeutics and Abzena, two service providers with expertise in biosimilar development, have partnered to support biosimilar development for third party customers. The companies plan to offer a “flexible and innovative approach from small scale biosimilar development through to large scale manufacturing.” 

Partnership
BioXpress Therapeutics and Abzena have partnered to provide support to third party customers for developing biosimilars • Source: Alamy

BioXpress Therapeutics, known for developing monoclonal antibody biosimilars, has entered into a partnership with contract development and manufacturing organization Abzena – that provides patient solutions for biologics and bioconjugates – to support biosimilar development for third party customers.

According to the companies, the partnership “creates an integrated solution between two service providers with expertise in biosimilar development and...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.